Day One Biopharmaceuticals (DAWN)
(Delayed Data from NSDQ)
$7.21 USD
+0.22 (3.15%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $7.20 -0.01 (-0.14%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
DAWN 7.21 +0.22(3.15%)
Will DAWN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for DAWN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DAWN
Monte Rosa Therapeutics (GLUE) Soars 44.1%: Is Further Upside Left in the Stock?
Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 303.46%: Here's is How to Trade
DAWN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates
Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates
Other News for DAWN
DAWN forms Bollinger Band Squeeze on September 18
DAWN forms Bollinger Band Squeeze on September 16
Is DAWN ready to move higher? Non-ADX 1,2,3,4 Bullish shows up after rising 0.84%
Fell Below 20 Day Moving Average appears for DAWN after 3.39% move
Is DAWN poised for gains? 20 Day Moving Average Support shows up after climbing 1.52%